March 24, 2025--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology ...

The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond ...

Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second half of 2025. Perspective from John A. Hovanesian, MD, FACS Alcon will expand its ...

Alcon, the multinational pharmaceuticals company specializing in eye care, has agreed a deal to acquire cataract laser surgery pioneer Lensar. The deal, valued at up to $430 million, will expand Alcon ...

Alcon has signed a definitive merger agreement to acquire Lensar to enhance its portfolio of cataract equipment and technology. Valued at nearly $356m, the acquisition will enhance Alcon's ...

The LENSAR Inc (LNSR) reports a 38% revenue increase in Q4 2024, driven by strong ALLY system placements and expanding market share. ORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR ...

Alcon (ALC) and Lensar (LNSR) announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire Lensar. The acquisition includes Ally Robotic Cataract ...

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating LENSAR (NASDAQ: LNSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon. Click here to ...

Alcon ALC and LENSAR, Inc. LNSR, a global medical technology company focused on advanced laser solutions for the treatment of cataracts, recently entered into a definitive merger agreement.

Alcon (ALC) and LENSAR (LNSR) have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment System ...